This article is for informational purposes only and does not constitute medical advice. Clinical trial eligibility and availability vary. Always consult a qualified healthcare professional before making any medical decisions or considering participation in a clinical trial.
Summary
Migraine affects approximately 1 billion people worldwide and is among the leading causes of disability. The CGRP (calcitonin gene-related peptide) revolution has transformed both acute and preventive treatment: four CGRP monoclonal antibodies are now approved for prevention, and gepant small molecules serve both acute and preventive roles. In 2026, trials are expanding these approaches to cluster headache — one of medicine's most painful conditions — and validating non-invasive neuromodulation as drug-free alternatives.
CGRP Monoclonal Antibodies for Prevention
Calcitonin gene-related peptide is a neuropeptide released from trigeminal nerve terminals during migraine attacks. It causes vasodilation and sensitizes pain pathways. CGRP levels rise dramatically during attacks and return to baseline with resolution. This mechanistic insight drove the development of the first migraine-specific preventive drug class.
Four anti-CGRP antibodies are FDA-approved for migraine prevention: erenumab (Aimovig, targeting the CGRP receptor), fremanezumab (Ajovy), galcanezumab (Emgality), and eptinezumab (Vyepti, administered intravenously). All reduce monthly migraine days by 3–4 days on average versus placebo — approximately 50% of patients achieve ≥50% reduction. They are well-tolerated with minimal systemic effects since CGRP has limited CNS penetration by antibodies.
Current trials are focusing on: predictors of response (can biomarkers identify which antibody will work best for a given patient?), combination strategies (CGRP antibody + gepant for breakthrough treatment), and whether these drugs prevent chronification — the process by which episodic migraine becomes chronic (≥15 headache days/month).
Gepants: Oral CGRP Antagonists for Acute and Preventive Use
Unlike triptans (which are contraindicated in cardiovascular disease due to vasoconstriction), gepants have no vasoconstrictive properties, making them usable in patients with stroke, MI, or Raynaud's phenomenon.
Ubrogepant (Ubrelvy) and rimegepant (Nurtec ODT) are approved for acute migraine treatment. Rimegepant is uniquely approved for both acute treatment and preventive use (alternate-day dosing), the only oral drug with this dual indication. The COMMAND trial showed alternate-day rimegepant reduced migraine frequency by 4.3 days/month vs. 0.8 for placebo.
Atogepant (Qulipta) is an oral daily gepant approved specifically for episodic and chronic migraine prevention — the first oral daily CGRP antagonist in this role. The ADVANCE and PROGRESS trials showed 4–5 day reductions in monthly migraine days. Trials are ongoing comparing atogepant to CGRP antibodies in head-to-head design and evaluating it in medication-overuse headache.
Cluster Headache Trials
Cluster headache causes attacks of excruciating unilateral periorbital pain lasting 15–180 minutes, occurring in clusters of weeks to months. It is considered among the most painful conditions in medicine and has historically had very limited treatment options. CGRP biology appears central to cluster headache as well — CGRP levels are elevated during attacks.
Galcanezumab demonstrated significant reduction in cluster headache attack frequency in the ENFORCE trial for episodic cluster headache (cluster bout reduction from ~17 to ~9 attacks/week). However, results were negative in chronic cluster headache, underscoring mechanistic differences between the two subtypes.
Eptinezumab is in Phase 3 trials specifically for chronic cluster headache, and fremanezumab trials are ongoing in both episodic and chronic forms. The PRISM trial is testing a high-dose fremanezumab regimen during cluster periods. Non-invasive vagus nerve stimulation (gammaCore) received FDA clearance for cluster headache based on ACT1 and ACT2 trials showing acute and preventive benefit.
Non-Invasive Neuromodulation
For patients who prefer drug-free approaches or cannot tolerate medications, non-invasive neuromodulation devices are now backed by clinical trial evidence:
Remote electrical neuromodulation (Nerivio): A wearable arm device cleared by the FDA for acute and preventive migraine. The ACMR and PREMIUM trials showed it reduced acute migraine pain freedom in 37% vs. 18% for sham at 2 hours, and reduced monthly migraine days by 4.0 vs. 1.3 for sham in preventive use. Particularly useful in cardiovascular patients who cannot use triptans.
Single-pulse transcranial magnetic stimulation (sTMS, eNeura SpringTMS): FDA-cleared for migraine with aura and chronic migraine. Phase 3 data showed 38% of patients experienced pain freedom at 2 hours vs. 17% for sham.
External trigeminal nerve stimulation (Cefaly): A forehead device approved for acute treatment and prevention. European randomized controlled trials (PREMICE, ACME) support preventive efficacy with a 30-minute daily protocol.
Key Takeaways
- Four CGRP monoclonal antibodies are approved for migraine prevention; ~50% of patients achieve ≥50% reduction in migraine days.
- Rimegepant and atogepant offer oral preventive options for patients who prefer not to inject; atogepant showed 4–5 fewer migraine days/month.
- Galcanezumab reduced cluster headache attacks significantly in episodic cluster headache; trials in chronic cluster headache are ongoing with eptinezumab and fremanezumab.
- Non-invasive devices (Nerivio, Cefaly, sTMS) provide drug-free alternatives with clinical trial support, especially for cardiovascular-risk patients.
- Combination trials pairing CGRP antibodies with acute gepant therapy are exploring whether layered CGRP blockade improves outcomes beyond either alone.